Sheldon L. Koenig
2022 - Esperion Therapeutics
In 2022, Sheldon L. Koenig earned a total compensation of $3.8M as President and Chief Executive Officer at Esperion Therapeutics, a 51% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $500,500 |
|---|---|
| Option Awards | $2,052,139 |
| Salary | $683,333 |
| Stock Awards | $549,840 |
| Other | $13,600 |
| Total | $3,799,412 |
Koenig received $2.1M in option awards, accounting for 54% of the total pay in 2022.
Koenig also received $500.5K in non-equity incentive plan, $683.3K in salary, $549.8K in stock awards and $13.6K in other compensation.
Rankings
In 2022, Sheldon L. Koenig's compensation ranked 925th out of 5,538 executives tracked by ExecPay. In other words, Koenig earned more than 83.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 925 out of 5,538 | 83rd |
Division Manufacturing | 422 out of 3,000 | 86th |
Major group Chemicals And Allied Products | 152 out of 1,350 | 89th |
Industry group Drugs | 138 out of 1,253 | 89th |
Industry Pharmaceutical Preparations | 102 out of 907 | 89th |
Source: SEC filing on April 13, 2023.
Koenig's colleagues
We found two more compensation records of executives who worked with Sheldon L. Koenig at Esperion Therapeutics in 2022.
News
Esperion Therapeutics CEO Sheldon Koenig's 2023 pay falls 22% to $3M
April 11, 2024
Esperion Therapeutics CEO Sheldon Koenig's 2022 pay falls 51% to $3.8M
April 13, 2023
Esperion Therapeutics CEO Tim Mayleben's 2021 pay rises 19% to $8.2M
April 14, 2022
Portola Pharmaceuticals CEO Scott Garland's 2019 pay falls 24% to $4.4M
April 20, 2020